Background: Tumour expression of cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), erythroblastic leukaemia viral oncogene homologue-2 (ErbB2), Ki-67 and p53 in breast cancer are associated with poorer outcomes. We investigated in vivo changes of these proteins with neoadjuvant chemotherapy.
introduction
Despite major advancements in its management, breast cancer remains a major public health issue on a global scale [1] . The current algorithm in selecting therapies for breast cancer is based on a combination of clinical, pathological and molecular factors, including TNM (tumour-node-metastasis) staging, menopausal status, tumour hormone receptor and Her2-neu status. While almost all populations of patients with breast cancer benefit from chemotherapy [2] , molecular prognostic and predictive factors of response or resistance remain lacking in clinical practice to guide the selection of patients for chemotherapy. Conventional variables such as tumour size, nodal status and histological grade do not correlate well with sensitivity to specific types of chemotherapy drugs, and currently, the only established molecular predictive factors for treatment in breast cancer are estrogen receptor (ER) and progesterone receptor (PR) for endocrine therapy and human epidermal growth factor receptor-2 (HER-2) status for anti-HER2 therapy.
Neoadjuvant chemotherapy is effective in down-staging tumours, increasing both the proportion of patients with negative lymph nodes on pathological examination and the ability to perform breast-conserving surgery [3] . It also provides a unique opportunity to investigate expression of tumour-related genes and proteins during chemotherapy. With better understanding of molecular biology, steps in carcinogenesis are now being targeted by specific pharmacological agents through identification of new predictive biomarkers, transforming the practice of medical oncology. Discovery of such biomarkers in cancer treatment is rapidly evolving and is being investigated at the genetic (polymorphisms), transcriptional (messenger RNA expression) and protein level (immunohistochemistry staining).
Several retrospective breast cancer studies have suggested that tumour expression of cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), erythroblastic leukaemia viral oncogene homologue 2 (ErbB2), Ki-67 and p53 may be associated with more aggressive breast cancer phenotypes, poorer response to chemotherapy and inferior survival [4] [5] [6] [7] [8] . In this study, we compared serial tumour samples from individual patients after exposure to sequential cycles of doxorubicin (Adriamycin, Pfizer (Perth) Pty Ltd, Bentley, Australia) and docetaxel (Taxotere, Aventis Pharma, SA, France) and examined changes in tumour expression of COX-2, EGFR, ErbB2, p53, Ki-67, ER and PR with immunohistochemistry (IHC). We also correlated any significant changes in biomarker expression with tumour clinical response and progression-free survival (PFS). The aim was to identify subgroups of patients who may benefit from specific targeted therapies with the goal of improving survival.
patients and methods

patients and treatment
This was a prospective, single-centre, open-label randomised phase II study. The study population comprised 100 East Asian women with histologically or cytologically proven locally advanced or metastatic breast cancer, who had measurable primary breast tumour 2 cm or greater. Participants were randomised to one of two alternating sequences of doxorubicin (A) and docetaxel (T), starting either with doxorubicin 75 mg/m 2 or docetaxel 75 mg/ m 2 every 3 weeks for six cycles (A-T-A-T-A-T, n = 49; T-A-T-A-T-A, n = 51).
Bidimensional tumour assessments were carried out every cycle using the World Health Organisation (WHO) criteria for tumour clinical response. A total of four tumour core biopsies were obtained; before initiating treatment, 3 weeks after the first and second cycles of chemotherapy, and upon completion of six cycles of chemotherapy or at study withdrawal. The biopsies were carried out at approximately the same location each time for each patient. Locoregional treatment was planned after chemotherapy, followed by endocrine therapy as per institutional guidelines for patients with hormone receptor-positive disease. All patients were followed every 3-6 months in accordance to institutional guidelines after treatment completion. PFS was defined as the date of randomisation to the first date of documented disease progression. The institutional ethics committee approved the study protocol, and all participants provided written informed consent.
immunohistochemical analysis
Core biopsies were taken from the primary breast tumour and stored in formalin and subsequently embedded in paraffin. Five-millimetre sections, stained with haematoxylin and eosin, were obtained to identify viable morphologically representative areas of the specimen from which core biopsies were taken. Tissue cores with a diameter of 0.6 mm were punched and arrayed on a new paraffin block. Five-millimetre sections of these tissue array blocks were cut and placed on charged polylysine-coated slides for immunohistochemical analysis. [9, 10] . p53 expression was assessed according to both the staining intensity and percentage of positive-stained cells and graded from 0 to 3, with 0 being no staining; 1 when either the staining intensity is 1+ with <50% stained or 2+ with <20% stained; 2 when the staining intensity is 1+ with <50% stained, 2+ with >20% but <70% stained, or 3+ with <30% stained; and 3 when the staining intensity is 2+ with >70% stained or 3+ with >30% stained. A score of 0 was deemed negative, 1 as weak, 2 as moderate and 3 as strong for p53 expression.
ErbB2 expression was evaluated by IHC according to the manufacturer's recommended scoring system as follows: 0, no staining; 1+, weak, barely detectable membrane staining; 2+, weak to moderate complete membrane staining and 3+, strong complete membrane staining. A score of 0-2+ was considered negative and 3+ was positive.
ER and PR expression were considered positive when 1% or more tumour cells were immunostained [11] .
Ki-67 expression was quantified using a visual grading system. An estimated percentage of Ki-67-positive cells was determined and scored according to four categories organised in increasing percentage intervals: negative, 0%; low, 1%-20%; intermediate, 21%-30% and high, >30%.
response to chemotherapy-clinical assessment
Clinical response was categorised according to the WHO criteria using bidimensional measurements of target lesions. Clinical complete response (CR) was defined as the disappearance of all palpable tumour deposits. Partial response (PR) was defined as reduction of tumour volume ‡50%. Tumour reduction <50% or increase of tumour volume up to 25% was scored as stable disease. An increase of >25% or the appearance of new lesions was designated as progressive disease.
statistical methods
Analyses were conducted using SPSS v13.0 (SPSS Inc., Chicago, IL). Univariate and multivariate Cox proportional hazards modelling was carried out with PFS as the end point. Change in level of expression of biomarkers with treatment was assessed using the Friedman rank sum test. To assess if treatment response differed as a function of baseline expression, we conducted the Friedman rank sum test separately for each biomarker. Logistic regression was carried out to assess whether poor prognostic clinical factors (e.g. metastatic and T4 disease) may be related to IHC expression of certain biomarkers at baseline. Survival analysis was conducted using Kaplan-Meier and the log-rank test was employed to evaluate differences in survivorship. This was an exploratory biomarker study. A sample size of 100 patients was deemed to be adequate to allow stratification of the dataset based on hormone receptor status and still have sufficient numbers in each hormone receptor subgroup to obtain useful information on chemotherapy-induced changes in the various proteins analysed. (P = 0.12). The baseline tumour biomarker status by immunohistochemistry (IHC) is denoted in Table 2 .
baseline biomarker IHC status in relation to PFS, T4 stage and presence of metastases
On univariate analysis, ER negativity (P = 0.007), ErbB2 positivity (P < 0.001), EGFR positivity (P < 0.001), COX-2 positivity (P = 0.002) and p53 'moderate to strong' staining (P < 0.001) were negative predictors for PFS, but only ErbB2 (P = 0.007) remained significant, while ER trended towards significance (P = 0.07) on multivariate analysis (Table 3) . COX-2 overexpression at baseline was strongly associated with higher T stage [odds ratio (OR) = 4.43, P = 0.004] and the presence of metastases (OR = 3.89, P = 0.029). ErbB2 overexpression at baseline was associated with the presence of metastases (OR = 2.99, P = 0.034). In comparison, baseline ER, PR, EGFR, p53 and Ki67 status were not associated with T stage or presence of metastases.
serial changes in expression of biomarkers by immunohistochemistry in response to chemotherapy COX-2 expression. There was a statistically significant progressive downward trend in COX-2 expression with increasing cycles of chemotherapy for the entire cohort (P = 0.002; Figure 1A ). Subgroup analysis found this decrease in COX-2 expression to be predominant in clinical responders (responders, P = 0.003; nonresponders, P = 0.697; Table 4 , Figure 1B and C). COX-2-positive tumours at baseline (n = 37) showed a statistically significant reduction in COX-2 expression with chemotherapy (P < 0.001). This downward trend was most marked between the third cycle and after the final cycle of chemotherapy suggesting that this change occurred late during chemotherapy ( Figure 1A ). Tumours that were COX-2 positive both at baseline and after treatment had the worst outcome, while those that were COX-2 negative both at baseline and after treatment had the best outcome (mean PFS 25 versus 47 months, P = 0.011); tumours whose COX-2 status changed with treatment had intermediate PFS; tumours that were COX-2 positive but changed to negative had longer PFS than those that remained positive with chemotherapy (35 versus 25 months, P = 0.173) and shorter PFS than those that were negative both at baseline and after chemotherapy (35 versus 47 months, original article Annals of Oncology P = 0.178), although the differences were not statistically significant ( Figure 2A ). Another significant finding is related to ER status and COX-2 overexpression. For ER-positive and COX-2-positive tumours at baseline, a change to COX-2 negativity resulted in a statistically significant improvement in PFS compared with tumours that remained COX-2 positive (52 versus 27 months, P = 0.002; Figure 2B ). As for ER-negative and COX-2-positive tumours at baseline, the PFS is generally poor regardless of whether the tumour remained COX-2 positive or became negative after chemotherapy (18 versus 22 months, P = 0.716; Figure 2C ). Interestingly, all EGFR-positive (n = 14) and p53 'moderate to strong' staining tumours (n = 20) were also COX-2 positive (P = 0.002 and 0.008, respectively) at baseline.
other biomarkers. There were no significant changes in IHC expression for EGFR, ErbB2, p53, Ki-67, ER and PR with sequential cycles of neoadjuvant chemotherapy.
discussion
Advances in cancer biology have improved our understanding of tumorigenesis and critical pathways, allowing investigations of predictive biomarkers that may be targeted by chemotherapy or specific pharmacological agents. The overall aim of the study was to provide better insights into serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. As opposed to numerous neoadjuvant chemotherapy studies that compared changes in tumour biomarkers at only two time points, i.e. before and after completion of chemotherapy [12] [13] [14] , our study is the first to evaluate serial changes in protein expression after exposure to sequential cycles of chemotherapy at four different time points, allowing further understanding into the time-course changes in expression of biomarkers induced by chemotherapy as well as correlation of these changes with clinicopathological features and treatment outcome.
The most interesting finding in our study was COX-2 expression. Cyclooxygenases, which exist in two isoforms, COX-1 and COX-2, are rate-limiting enzymes in the formation of prostaglandins from arachidonic acid. Whereas COX-1 is considered to be constitutively expressed, COX-2 is highly inducible by various factors and is associated with tumorigenesis by enhancing angiogenesis [15, 16] , suppressing apoptosis [17] and promoting invasiveness and metastases [18] . 
Annals of Oncology original article
Consistent with these findings, several studies have shown the unfavourable prognostic significance of COX-2 expression in breast cancer, including inferior disease-free survival and higher incidence of metastatic disease [4, 19] . In concordance with published data, our study showed that COX-2-positive tumours at baseline correlated with more advanced T stage, presence of metastases and inferior PFS, compared with COX-2-negative tumours. With neoadjuvant chemotherapy, we demonstrated a reduction in COX-2 expression in breast tumours, which has also been previously observed in breast cancer cell lines after chemotherapy [20] . The reduction in COX-2 expression was most marked between the third and last cycle of chemotherapy, suggesting that an 'optimal' number of cycles of chemotherapy is required for this change to occur. This information would otherwise not be known if biopsies were obtained only in the beginning and at the end of chemotherapy. Furthermore, this reduction in COX-2 expression was seen mainly in clinical responders, a phenomenon also documented in ovarian and cervical carcinomas [21] . More importantly, we also demonstrated that the PFS for patients whose tumours changed from COX-2 positivity to negativity with chemotherapy may be better than that of patients whose tumours remained positive after chemotherapy, although this difference did not reach statistical significance, suggesting a potential role for COX-2 manipulation in the management of cancers. Another important finding in our study was that in patients with ER-positive and COX-2-positive tumours at baseline, post-chemotherapy COX-2 positivity had a significant negative influence on PFS, suggesting that COX-2 plays an important role in hormone-dependent breast cancers. COX-2-mediated prostaglandin E2 (PGE2) is a powerful stimulator of aromatase transcription, leading to increased concentrations of estrogens. Thus, postchemotherapy COX-2 expression may be the cause of progression of estrogen-dependent breast cancer by autocrine and paracrine mechanisms, either by direct stimulation of tumour-cell proliferation or by indirect up-regulation of aromatase activity [22] , despite the use of hormonal therapy after chemotherapy in endocrine-responsive tumours in our cohort of patients.
The intense interest in COX-2 expression in cancer stems from the fact that this phenomenon occurs in many human malignancies including breast, colon and lung cancer [19, 23, 24] , and the possibility of using widely available COX-2 inhibitors, e.g., nonsteroidal anti-inflammatory drugs, along with conventional anticancer therapy to enhance treatment efficacy. This is based on the premise that many of the COX-2-regulated genes that contribute to tumour progression may also be determinants of tumour sensitivity to treatment including chemotherapy and radiotherapy [25] . Although the potential chemopreventive properties of selective COX-2 inhibitors are being actively investigated, less is known about the utility of these agents in the treatment of cancer. There is emerging data from breast, pancreatic and lung cancer studies showing potential benefit of combining COX-2 inhibitors with chemotherapy [26] [27] [28] . In particular, a recent study involving patients with heavily pretreated breast cancer showed that the combination of chemotherapy and a selective COX-2 inhibitor, celecoxib, resulted in a statistically significant doubling of time to progression for COX-2-positive tumours compared with COX-2 negative ones. Older studies combining the use of COX-2 inhibitors and chemotherapy have previously yielded disappointing results. A possible reason for this is poor patient selection, as these studies enrolled all-comers rather than COX-2-positive patients [29, 30] . Furthermore, we believe that, from our study, the breast cancer patients who will truly benefit from COX-2 inhibition in combination with chemotherapy are those whose tumours remained positive despite chemotherapy. This argues for the increasing relevance of reexamining histological specimens after primary or initial treatment. However, this treatment strategy is challenging to implement as we are currently unable to predict which tumours will retain positivity or convert to negative after treatment with chemotherapy as this change in COX-2 status tend to occur after several cycles of chemotherapy. Excitingly, based on our findings, it would be logical to postulate that patients with ER-positive and COX-2-positive tumours at baseline and that remained COX-2 positive upon completion of chemotherapy may benefit most from the combination of COX-2 inhibition and hormonal therapy with the aim of prolonging PFS as inhibition of PGE2 by COX-2 inhibitors may inhibit aromatase activity and combination with aromatase inhibitors may reduce tumours by inhibiting a common target. This feasible strategy should be explored in a larger randomised controlled study.
Our study also noted possible correlations between COX-2 expression with EGFR and p53 expression. PGE2, derived from the action of COX on arachidonic acid, causes increased tyrosine phosphorylation of EGFR and therefore its activation Refers to sample size that has the full complement of four tumour biopsies for COX-2 immunohistochemical analysis. b S0, biopsy at baseline; S1, biopsy 3 weeks after cycle 1 chemotherapy; S2, biopsy 3 weeks after cycle 2 chemotherapy; S3, biopsy after completing six cycles of chemotherapy or upon study withdrawal. COX-2, cyclooxygenase-2; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
original article Annals of Oncology [31] . COX-2 has also been implicated in the inhibition of DNA damage and induction of apoptosis mediated by p53 and a direct association between high COX-2 content and overexpression of p53 has been reported in ovarian tumours [32] . Consistent with previous neoadjuvant breast cancer studies, we did not find significant changes in IHC expression of ER, PR, ErbB2 and p53 with chemotherapy [12, 14] . Changes in Ki-67 expression in breast cancer with neoadjuvant chemotherapy have produced mixed results [14, 33] . A change in Ki-67 expression was not found in our study. To our knowledge, no breast cancer studies to date have explored changes in EGFR expression with neoadjuvant chemotherapy. We did not find a change in EGFR expression in the breast tumour after neoadjuvant chemotherapy. This is consistent with what has been reported in non-small-cell lung carcinomas, where alterations in EGFR IHC following neoadjuvant chemotherapy are very uncommon [34] .
Limitations of our study should be highlighted. First, the existence of tumour heterogeneity has led to concerns that core biopsies may not be representative of the tumour tissue as a whole as they are often restricted to the superficial aspects of the tumour. Secondly, while immunohistochemistry is relatively inexpensive, it is neither quantitative nor objective, involving subjective grading and often lacks standard scoring systems.
conclusions In summary, limited scale, focused profiling of primary tumours from high-risk breast cancer patients may yield useful information to guide target-specific therapy. We found that chemotherapy resulted in changes in COX-2 expression in breast cancer. A change in expression from positivity to negativity was mainly observed among chemotherapy responders and was associated with numerically longer PFS. In addition, it appears that COX-2 plays an important role in hormone-dependent breast cancers and that a certain subgroup of these patients may benefit from COX-2 inhibition. Further research is warranted to understand its relationship with chemotherapy response and hormonal pathways and explore strategies to manipulate it for therapeutic benefit. 
